Home
  • E-mailJorn.Vold@uib.no
  • Phone+47 55 21 20 86
  • Visitor Address
    Alrek helseklynge, blokk D, Årstadveien 17
  • Postal Address
    Postboks 7804
    5020 Bergen
Academic article
  • Show author(s) 2021. Validation of a three-item Fatigue Severity Scale for patients with substance use disorder: a cohort study from Norway for the period 2016–2020. Health and Quality of Life Outcomes. 10 pages.
  • Show author(s) 2021. Substance use and symptoms of mentalhealth disorders: a prospective cohort of patients with severe substance use disorders in Norway. Substance Abuse Treatment, Prevention, and Policy. 10 pages.
  • Show author(s) 2021. Subjective symptoms and serum methadone concentrations: what should guide dose adjustments in methadone maintenance treatment? A naturalistic cohort study from Norway. Substance Abuse Treatment, Prevention, and Policy. 1-8.
  • Show author(s) 2021. Integrated treatment of hepatitis C virus infection among people who inject drugs: A multicenter randomized controlled trial (INTRO-HCV). PLoS Medicine.
  • Show author(s) 2021. Changes in substance use during outpatient treatment for substance use disorders: a prospective Norwegian cohort study from 2016 to 2020. Substance Abuse Treatment, Prevention, and Policy. 1-9.
  • Show author(s) 2020. Uptake and predictors of direct-acting antiviral treatment for hepatitis C among people receiving opioid agonist therapy in Sweden and Norway: a drug utilization study from 2014 to 2017. Substance Abuse Treatment, Prevention, and Policy.
  • Show author(s) 2020. Too much or too little opioids to patients receiving opioid agonist therapy in Norway (2013-2017): a prospective cohort study. BMC Health Services Research. 10 pages.
  • Show author(s) 2020. Potentially addictive drugs dispensing to patients receiving opioid agonist therapy: a register-based prospective cohort study in Norway and Sweden from 2015 to 2017. BMJ Open. 10 pages.
  • Show author(s) 2020. On the path towards universal coverage of hepatitis C treatment among people receiving opioid agonist therapy (OAT) in Norway: A prospective cohort study from 2013 to 2017. BMJ Open. 1-9.
  • Show author(s) 2020. Impact of clinical and sociodemographic factors on fatigue among patients with substance use disorder: a cohort study from Norway for the period 2016–2020. Substance Abuse Treatment, Prevention, and Policy. 11 pages.
  • Show author(s) 2020. Health-related quality of life of long-term patients receiving opioid agonist therapy: a nested prospective cohort study in Norway. Substance Abuse Treatment, Prevention, and Policy. 1-12.
  • Show author(s) 2020. Dispensations of benzodiazepines, z-hypnotics, and gabapentinoids to patients receiving opioid agonist therapy; A prospective cohort study in Norway from 2013 to 2017. BMC Health Services Research. 1-12.
  • Show author(s) 2020. Dispensation of attention deficit hyperactivity disorder (ADHD) medications in patients receiving opioid agonist therapy; A national prospective cohort study in Norway from 2015 to 2017. BMC Psychiatry. 1-12.
  • Show author(s) 2019. Integrated treatment of hepatitis C virus infection among people who inject drugs: study protocol for a randomised controlled trial (INTRO-HCV). BMC Infectious Diseases. 1-9.
Feature article
  • Show author(s) 2020. Kvetiapinmisbruk-myte eller realitet? Tidsskrift for Den norske legeforening. 1-5.
Academic literature review
  • Show author(s) 2019. Integrated care of severe infectious diseases to people with substance use disorders; a systematic review. BMC Infectious Diseases. 1-15.

More information in national current research information system (CRIStin)